retatrutide phase 2 trial results obesity Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide Results: 28.3% Weight Loss

Description

These predispositions should be interpreted with a qualified healthcare provider and do not predict exact medication response

This therapeutic effect has also been explored in patients with obesity and major depressive disorder, a population often affected by overlapping pathophysiological processes such as insulin resistance, inflammation, and altered reward system function [33,42,70]

While king Keytruda, Mercks stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S

In general, there was a significant association between treatment with GLP-1 RAs and the occurrence of GLP-1 RA-related psychiatric AEs (ROR = 1.62, 95% CI = 1.561.69), which varied with respect to the different GLP-1 RAs ( Figure 3C )

Accumulating evidence supports the notion that the effects of GLP-1 on gastrointestinal functions are mediated through its distinct receptors on vagal nerves both in animals and man (79-81)